Evidence of subgroup-specific treatment effect in the absence of an overall effect: Is there really a contradiction?

Pharmacoepidemiology and Drug Safety

Volumn 22, Issue 11, 2013, Pages 1178-1188

  Abrahamowicz, Michal ^a,b   Beauchamp, Marie Eve ^b   Fournier, Pierre ^c   Dumont, Alexandre ^d  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^d INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

Author keywords

Interaction test; Pharmacoepidemiology; Simulations; Subgroup analysis

Indexed keywords

ARTICLE; PRIORITY JOURNAL; SIMULATION; THERAPY EFFECT; TREATMENT OUTCOME;

INTERACTION TEST; PHARMACOEPIDEMIOLOGY; SIMULATIONS; SUBGROUP ANALYSIS;

CLINICAL TRIALS AS TOPIC; COMPUTER SIMULATION; DATA INTERPRETATION, STATISTICAL; EPIDEMIOLOGIC RESEARCH DESIGN; HUMANS; PHARMACOEPIDEMIOLOGY; RESEARCH DESIGN; SAMPLE SIZE; TREATMENT OUTCOME;

EID: 84886258553     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3485     Document Type: Article

References (19)

1. Knol MJ, Egger M, Scott P, et al. When one depends on the other: reporting of interaction in case-control and cohort studies. Epidemiology 2009; 20: 161-166.
2. Pocock SJ, Assmann SE, Enos LE, et al. Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practice and problems. Stat Med 2002; 21: 2917-2930.
3. Carle AC. Mitigating Systematic Measurement Error in Comparative Effectiveness Research in Heterogeneous Populations. Med Care 2010; 48: S68-S74.
4. Greenfield S, Kravitz R, Duan N, et al. Heterogeneity of treatment effects: Implications for guidelines, payment, and quality assessment. Am J Med 2007; 120: 3-9.
5. Fang HB, Ross DD, Sausville E, et al. Experimental design and interaction analysis of combination studies of drugs with log-linear dose responses. Stat Med 2008; 27: 3071-3083.
6. Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. Can Med Assoc J 2009; 180: 713-718.
7. Fortin PR, Abrahamowicz M, Ferland D, et al. Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2008; 59: 1796-1804.
8. Lacaille D, Guh DP, Abrahamowicz M, et al. Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis. Arthritis Rheum 2008; 59(8): 1074-1081.
9. Brookes ST, Whitely E, Egger M, et al. Subgroup analyses in randomized trials: risks of subgroup-specific analyses; power and sample size for the interaction test. J Clinic Epidemiol 2004; 57: 229-236.
10. Kaufman JS. Interaction reaction. Epidemiology 2009; 20: 159-160.
11. Brookes ST, Whitley E, Peters TJ et al. Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives. Health Technol Assess 2001; 5: 1-56.
12. Weiss NS. Subgroup-specific associations in the face of overall null results: should we rush in or fear to tread? Cancer Epidemiol Biomarkers Prev 2008; 17: 1297-1299.
13. PASS 2008. NCSS, LLC: Kaysville, Utah; 2008.
14. R: A language and environment for statistical computing. R Foundation for Statistical Computing: Vienna, Austria; 2010.
15. Yang XL, So WY, Ma RCW, et al. Low HDL Cholesterol, Metformin Use, and Cancer Risk in Type 2 Diabetes The Hong Kong Diabetes Registry. Diabetes Care 2011; 34: 375-380.
16. Boutitie F, Gueyffier F, Pocock SJ, et al. Assessing treatment-time interaction in clinical trials with time to event data: a meta-analysis of hypertension trials. Stat Med 1998; 17: 2883-2903.
17. Schmoor C, Schumacher M. Effects of covariate omission and categorization when analysing randomized trials with the Cox model. Stat Med 1997; 16: 225-237.
18. Rothman KJ, Greenland S, Walker AM. Concepts of interaction. Am J Epidemiol 1980; 112: 467-470.
19. Greenland S Interactions in epidemiology: relevance, identification, and estimation. Epidemiology 2009; 20: 14-17.